FierceBiotechOriginal article
{"a":[{"_":"Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2","$":{"href":"/biotech/solstice-rises-225m-advance-second-gen-ctla-4-immunotherapy","hreflang":"en"}}]}
next-gen CTLA-4 immunotherapyPositive
AI Analysis
Summary
Solstice Oncology secured $225 million in Series A funding to advance a next-generation CTLA-4 immunotherapy into Phase 2 clinical trials for cancer treatment.
Clinical Trial Data
Phase
2
Importance:6/10
Sentiment:
0.70
fundingseries AimmunotherapyCTLA-4oncology
Related Companies
Read the original article
Published by FierceBiotech on September 9, 2026 12:08 AM